TMCnet News
Axoft Unveils Meaningful Clinical Momentum of Its Ultra-Soft Fleuron™ Brain Computer Interface ProbesAxoft, a neurotechnology company, today announced multiple data milestones from ongoing clinical use of its ultra-soft Fleuron™ Brain Computer Interface (BCI) depth probes at Mass General Brigham (MGB) and The Panama Clinic. Built to leverage the naturally scalable language of the brain, Axoft's high-density BCIs use the company's proprietary Fleuron material, which enables high quality neural data capture over longer periods of time due to the material's superior biocompatibility. Axoft's BCIs have already demonstrated the ability to safely decode brain signals, and offer a path for improving the standard of care for prognosis and communication in disorders of consciousness. "Every year in the U.S., traumatic brain injuries lead to 2.9 million emergency room visits, with many patients ending up in an unresponsive state. Physicians will look for signs of consciousness by prompting a response, but consciousness and the ability to respond are not the same," said Dr. Paul Le Floch, co-founder and CEO of Axoft. "Axoft is measuring consciousness directly from the brain to provide a much-needed voice to the almost half (43%) of neuro-ICU patients who are misdiagnosed when it comes to their state of consciousness. This clinical momentum demonstrates our progress in safely collecting vital neural data to transform how patients who are in comas, vegetative states or minimally conscious states are assessed and treated, with long-term applications potentially extending into treatments for epilepsy, movement disorders and other neurological conditions." Axoft's latest clinical results include:
About Axoft Founded in 2021 and headquartered in Cambridge, Massachusetts, Axoft is building implantable Brain-Computer Interfaces (iBCIs) leveraging bio-inspired materials to enable a seamless interface between the brain and electronics, and allow for measurement and stimulation at high-resolution in any brain region. Axoft is on a mission to unlock new treatments for patients suffering from neurological disorders by producing iBCIs that answer critical unmet needs. For more information, visit www.axoft.us or follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261119071329/en/ |

